Ocean Outpost pp 141-150 | Cite as

Ocean Medicine

  • Erik Seedhouse


In the field of pharmaceutical development, there is a problem. Nearly half of all new drugs are derived from terrestrial microorganisms, but because the soil has been exploited to the limit, there are few drugs left to discover. This has forced pharmaceutical companies to abandon many of their soil-based research and development programs and search for new drugs in other locations, such as the ocean. The good news is that the prospect of finding a new drug in the ocean, especially among coral reef species, may be 300-400 times more likely than isolating one from a terrestrial ecosystem. Although terrestrial organisms exhibit great species diversity, marine organisms have greater phylogenetic diversity. In fact, thousands of marine species have never been studied and the potential of these marine organisms as sources of medicines has created a renaissance of interest in exploring the deep ocean.


Bone Graft Marine Natural Product Federal Drug Administration Marine Biotechnology Marine Coral 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Proksch, P.; Edrada-Ebel, R.A.; Ebel, R. Drugs from the Sea—Opportunities and Obstacles. Marine Drugs, 1, 5–17 (2003).CrossRefGoogle Scholar
  2. [2]
    Kerr, R.G.; Kerr, S.S. Marine Natural Products as Therapeutic Agents. Expert Opinion on Therapeutic Patents, 9, 1207–1222 (1999).CrossRefGoogle Scholar
  3. [3]
    Newman, D.J.; Cragg, G.M. Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials. Journal of Natural Products, 67, 1216–1238 (2004).CrossRefGoogle Scholar
  4. [4]
    Olivera, B.M. ω-Conotoxin MVIIA: From Marine Snail Venom to Analgesic Drug. In: N. Fusetani (ed.), Drugs from the Sea, p. 74. Karger, Basel (2000).CrossRefGoogle Scholar
  5. [5]
    Rinehart, K.; Holt, T.G.; Fregeau, N.L.; Stroh, J.G.; Kiefer, P.A.; Sun, F.; Li, L.; Martin, D.G. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent Antitumor Agents from the Caribbean Tunicate Ecteinascidia turbinata. Journal of Organic Chemistry, 55, 4512–4515 (1990).CrossRefGoogle Scholar
  6. [6]
    Pettit, G.R.; Kamano, Y.; Herald, C.L.; Tuinman, A.A.; Boettner, F.E.; Kizu, H.; Schmidt, J.M.; Baczynskyj, L.; Tomer, K.B.; Bontems, R.J. The Isolation and Structure of a Remarkable Marine Animal Antineoplastic Constituent: Dolastatin 10. Journal of the American Chemical Society, 109,6883–6885 (1987).CrossRefGoogle Scholar
  7. [7]
    Turner, T.; Jackson, W.H.; Pettit, G.R.; Wells, A.; Kraft, A.S. Treatment of Human Prostate Cancer Cells with Dolastatin-l0, a Peptide Isolated from a Marine Shell-Less Mollusc. Prostate, 34, 175–181 (1998).CrossRefGoogle Scholar
  8. [8]
    Vuola, J.T.; Böhling, T.; Kinnunen, J.; Hirvensalo, E.; Asko-Seljavaara, S. Natural Coral as Bone-Defect-Filling Material. Journal of Biomedical Materials Research, 51(1), 117–122 (2000).CrossRefGoogle Scholar
  9. [9]
    Parikh, S.N. Bone Graft Substitutes: Past, Present, Future. Journal of Postgraduate Medicine, 48(2), 142–148 (2002).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Erik Seedhouse
    • 1
  1. 1.MiltonCanada

Personalised recommendations